You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, Large B-Cell, Diffuse

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Molecular Classification of Relapsed/Refractory Diffuse Large

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Gene Expression Profiling
  • Gene expression profile
  • Shanghai, Shanghai, China
    Yian Zhang
Mar 31, 2022

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 9, 2023

Lymphoma, Large B-Cell, Diffuse, Fatigue Trial in Columbus (Fatigue Reduction Diet)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Fatigue
  • Fatigue Reduction Diet
  • Columbus, Ohio
    The Ohio State University
Apr 26, 2022

Chidamide in Recurrent and Refractory Diffuse Large b

Enrolling by invitation
  • Diffuse Large B-cell Lymphoma
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
Jan 9, 2023

Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B Cell Lymphoma
  • Glofitamab, Poseltinib, Lenalidomide
  • Seoul, Korea, Republic of
    Seoul National University Hospital
May 30, 2022

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 23, 2023

Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • loncastuximab tesirine
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Jun 24, 2022

Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation

Recruiting
  • Lymphoma, Large B-Cell, Diffuse
    • Copenhagen, Denmark
      Department of Hematology, Rigshospitalet
    Jan 12, 2022

    Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    May 4, 2022

    Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy Trial (ultra-fraction radiotherapy)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • ultra-fraction radiotherapy
    • (no location specified)
    Aug 22, 2022

    Lymphoma, Large B-Cell, Diffuse Trial in Saint Louis, Columbus (Brentuximab vedotin, Lenalidomide)

    Completed
    • Lymphoma, Large B-Cell, Diffuse
    • Saint Louis, Missouri
    • +1 more
    Feb 16, 2022

    Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    Jan 20, 2023

    Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma

    Completed
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • CAR-T
    • Allo-HSCT cohort
    • East Hanover, New Jersey
      Novartis Investigative Site
    Jun 29, 2022

    Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Itacitinib
    • Chimeric antigen receptor (CAR) T-cell therapy
    • Tampa, Florida
      Moffitt Cancer Center
    Mar 6, 2023

    Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    Apr 24, 2022

    Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • anti-CD19 CAR NK cells
    • (no location specified)
    Dec 21, 2022

    Large B-Cell Lymphoma, DLBCL Trial (Tafasitamab, Lenalidomide)

    Not yet recruiting
    • Large B-Cell Lymphoma
    • Diffuse Large B-Cell Lymphoma
    • (no location specified)
    Jun 17, 2022

    Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

    Recruiting
    • Diffuse Large B Cell Lymphoma，DLBCL
    • PM 8.4 mg/m2
    • PM 11.2 mg/m2
    • Chengdu, Sichuan, China
      West China Hospital Sichuan University
    Jan 15, 2023

    Diffuse Large B-cell Lymphoma Trial in Wuhan (Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • Mitoxantrone Hydrochloride Liposome
    • +2 more
    • Wuhan, Hubei, China
      Department of Hematology Tongji Hospital, Tongji Medical College
    Oct 7, 2022

    18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma

    Completed
    Has Results
    • Lymphoma, Large B-Cell, Diffuse
    • FDG PET radiomic feature evaluation
    • Hangzhou, Zhejiang, China
      Second Affiliated Hospital, School of Medicine, Zhejiang Univers
    Sep 27, 2021

    Diffuse Large B Cell Lymphoma Trial in Shanghai (zanubrutinib)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 13, 2022

    Diffuse Large B Cell Lymphoma Trial in Wenzhou (Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Wenzhou, Zhejiang, China
      First Affiliated Hospital of Wenzhou Medical University
    Jun 20, 2022

    Resistance to GNC-038 in Relapsed and Refractory Diffuse Large

    Recruiting
    • Diffuse Large B Cell Lymphoma
      • Shanghai, Shanghai, China
        Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
      Apr 17, 2022

      Tisagenlecleucel in Brazilian Acute Lymphoblastic Leukemia or

      Not yet recruiting
      • Diffuse Large B-cell Lymphoma
      • Acute Lymphoblastic Leukemia
      • tisagenlecleucel
      • (no location specified)
      Sep 13, 2022